**Name of Journal:** *World Journal of Nephrology*

**Manuscript NO:** 80194

**Manuscript Type:** REVIEW

**Acute kidney injury due to bilateral malignant ureteral obstruction: Is there an optimal mode of drainage?**

Gadelkareem RA *et al*. Bilateral malignant ureteral obstruction

Rabea Ahmed Gadelkareem, Ahmed Mahmoud Abdelraouf, Ahmed Mohammed El-Taher, Abdelfattah Ibrahim Ahmed

**Rabea Ahmed Gadelkareem, Ahmed Mahmoud Abdelraouf, Ahmed Mohammed El-Taher, Abdelfattah Ibrahim Ahmed,** Department of Urology, Assiut Urology and Nephrology Hospital, Faculty of Medicine, Assiut University, Assiut 71515, Assiut, Egypt

**Author contributions:** Gadelkareem RA and Abdelraouf AM designed the research, searched and collected the data, and wrote the paper; El-Taher AM and Ahmed AI contributed to design, writing and revision, and supervised the work; all authors revised and approved the paper.

**Corresponding author: Rabea Ahmed Gadelkareem, MD, Assistant Professor,** Department of Urology, Assiut Urology and Nephrology Hospital, Faculty of Medicine, Assiut University, Elgamaa Street, Assiut 71515, Assiut, Egypt. dr.rabeagad@yahoo.com

**Received:** September 19, 2022

**Revised:** October 29, 2022

**Accepted:** November 30, 2022

**Published online:**

**Abstract**

There is a well-known relationship between malignancy and impairment of kidney functions, either in the form of acute kidney injury or chronic kidney disease. In the former, however, bilateral malignant ureteral obstruction is a surgically correctable factor of this complex pathology. It warrants urgent drainage of the kidneys in emergency settings. However, there are multiple controversies and debates about the optimal mode of drainage of the bilaterally obstructed kidneys in these patients. This review addressed most of the concerns and provided a comprehensive presentation of this topic from the recent literature. Also, we provided different perspectives on the management of the bilateral obstructed kidneys due to malignancy. Despite the frequent trials for improving the success rates and functions of ureteral stents, placement of a percutaneous nephrostomy tube remains the most recommended tool of drainage due to bilateral ureteral obstruction, especially in patients with advanced malignancy. However, the disturbance of the quality of life of those patients remains a major unresolved concern. Beside the unfavorable prognostic potential of the underlying malignancy and the various risk stratification models that have been proposed, the response of the kidney to initial drainage can be anticipated and evaluated by multiple renal prognostic factors, including increased urine output, serum creatinine trajectory, and time-to-nadir serum creatinine after drainage.

**Key Words:** Acute kidney injury; Kidney; Malignancy; Percutaneous nephrostomy; Ureteral obstruction; Ureter

Gadelkareem RA, Abdelraouf AM, El-Taher AM, Ahmed AI. Acute kidney injury due to bilateral malignant ureteral obstruction: Is there an optimal mode of drainage? *World J Nephrol* 2022; In press

**Core Tip:** Acute kidney injury due to malignant ureteral obstruction is a complex nephrological and urological emergency. Its management includes an initial resuscitation of the metabolic abnormalities, minimally invasive drainage of the obstructed kidneys, and correction of the underlying etiology. Several prognostic models have been proposed to clarify the best approach. However, there are controversies about the optimal mode of drainage of the kidneys, regarding the tool and laterality of drainage. Despite the practical preference of using the percutaneous nephrostomy rather than the double-J stent, the optimal mode of drainage has not been defined yet. The parameters of kidney response to drainage and the status of the underlying malignancy are important prognostic factors.

**INTRODUCTION**

Acute kidney injury (AKI) is defined as an increase in serum creatinine (SCr) of ≥ 0.3 mg/dL (≥ 26.5 μmol/l) within 48 h or ≥ 1.5 times from the baseline within 7 d[1,2]. Classically, this biochemical definition is practically translated into a rapid deterioration of kidney functions within hours or days. It is a reversible pathology when properly managed in a timely manner. According to the positional relationship between the original pathology and the kidney of the affected patient, AKI has classically been classified into prerenal (hypovolemic), renal (intrinsic), and postrenal (obstructive; Po-AKI) AKI[2-4]. The latter class represents a urological emergency when the patient presents with disturbed kidney functions, such as an elevated SCr level. The underlying pathology of Po-AKI is the obstruction of the two kidneys or one kidney in patients with a solitary functioning kidney.

The obstruction can occur at any point along the course of the ureters. This obstruction can be caused by either benign causes such as urolithiasis or malignant causes such as bladder cancer. Kidney obstruction with elevated function warrants drainage of the kidneys as fast as possible. Methods of drainage include placement of ureteral stents or percutaneous nephrostomy (PCN) tubes. Currently, there has been no consensus on the optimal mode of drainage (method and laterality) in these cases[5,6]. Malignant ureteral obstruction (MUO) represents a more complex entity than the benign ureteral obstruction (BUO) in the field of AKI because the former has a mechanical factor (the obstruction) and a metabolic factor (the malignancy).

These variables have generated many controversies on the different aspects of the management of patients with AKI due to malignant bilaterally obstructed kidneys (BOKs). They may affect the decision-making for the mode of drainage, uncertainty of renal responses after drainage, benefits in the management of the underlying disease, and effects on patient quality of life (QoL) with the different methods of drainage[6-8]. In this commentary review, we addressed these different aspects in patients with Po-AKI due to MUO. The relevant recent literature from the last two decades was reviewed for the available approaches of drainage of BOKs in patients with MUO. The scope of the review was to clarify the efficiency of these approaches and the differences and similarities between them.

**DESCRIPTION OF SUMMARIZED LITERATURE**

The relevant findings from the literature are summarized as relevant findings per study (Table 1) and as a comparison of the technical and practical characteristics (Table 2). In Table 1, 36 studies were reviewed and listed in a chronological manner, including five retrospective studies published from 2000 to 2004[9-13], but one of them included patients with BUO and MUO[9]. In 2005, however, another study included patients with BUO and MUO[14], while there were another five studies that included patients with only MUO[15-19]. Only one study was found suitable in 2006, including 151 patients with MUO[20]. In 2007, three retrospective studies were reviewed with various numbers of patients[21-23]. However, five retrospective studies were found in 2008 and 2009[24-28], and three of them had comparative designs[25,27,28]. In 2010, the first prospective study was published within the time frame of this review[29]. Between 2011 and 2015, we included four retrospective studies[30-33], and only one of them had a comparative design[32]. Also, between 2016 and 2019, only four studies were reviewed[34-37], but they included two comparative studies[36,37] and one prospective study[34]. Furthermore, we included three studies published in 2020[8,38,39], one comparative study in 2021[40], and three studies in 2022[5,41,42]. Table 1 included only four prospective studies[5,29,34,40], one large data base study[8], and two multicenter studies[39,40]. Regarding the comparative data presented in Table 2, they were formulated from the studies listed in Table 1[9,12-14,17,21,33] and from other relevant studies[43,44]. Many prognostic and risk stratification models have been proposed so far[23,24,26,40]. They are based on variables from the patient and underlying pathology. However, the sharp stratification of these patients and solid guidelines have not been settled yet[24,26,30,34,40]. These reviewed findings will be addressed and discussed in the different sections of this review.

**INCIDENCE**

The incidence of AKI has been estimated by The National Institute for Health and Care Excellence as 13%-18% of people admitted to the hospital[45]. It mainly involves the elderly and has a mortality rate of 10%-80%[45,46]. Globally, AKI affects over 13 million people per year and results in 1.7 million deaths. Four in five cases of AKI occur in the developing world[47,48]. Po-AKI represents 5%-10% of all AKI cases[49]. However, it can represent up to 22% of AKI cases among the elderly[50] and 7.6% of the intensive care patients. Po-AKI due to MUO may represent up to 10% of cases with Po-AKI and 18% of patients with malignancy diagnosed within 1 year[51].

**PATHOPHYSIOLOGY**

***Etiological classification of Po-AKI***

Po-AKI is caused by urinary tract obstruction, when this obstruction affects the both functioning kidneys, a solitary kidney, or an only-functioning kidney. Relative to the origin of the obstructing pathology, the mechanism and causes of ureteral obstruction are classified into extraluminal compression, stenosis due to a mural pathology, and intraluminal lodgments. The three most common causes of renal obstruction in adults are urinary stones, malignancy, and iatrogenic benign strictures[6,7]. Hence, these causes are either malignant or benign pathologies. The benign causes include urinary tract stones, ureteral strictures, and retroperitoneal fibrosis[7]. However, the malignant causes include both urological and extraurological malignancies[5,6]. The urological carcinomas of the urinary bladder[10,52] and prostate cancer[18] are the most common causes of MUO. The extraurological malignancies include colorectal cancer[5], cervical and uterine cancers[27], adnexal cancers, and systemic malignancy such as lymphoma and metastases (Table 1)[5,51].

***Pathophysiological mechanisms of Po-AKI with MUO***

**Obstruction-based mechanisms:** There are multiple intrinsic pathophysiological mechanisms of AKI with BOKs, including hemodynamic instability, microcirculatory disorders (such as endothelial dysfunction and microvascular thrombosis), inflammation, tubular cell injury, renal venous congestion, tubular obstruction, and auto-immune processes[53]. Reductions in renal blood flow represent a common pathologic pathway for decreasing the glomerular filtration rate in all these mechanisms[54]. However, the most likely explanation is that one adopting an occurrence of alterations in the glomerulo-tubular dysfunction due to urine flow obstruction[55]. In the early hours of obstruction of the kidney, the intraluminal pressure is transferred to the renal tubules and to Bowman’s space[55]. The transferred pressure results in a decreased filtration pressure in the glomerular capillary walls. After 2-3 h of obstruction, a prostaglandin-mediated myogenic change in the afferent arterioles increases the renal blood flow, which normalizes within 5 h.

After 1 d, the renal and intraglomerular blood flow decreases as a result of the intrarenal production of thromboxane A2 and angiotensin II. These products are strong vasoconstrictors of the afferent and efferent arterioles and contribute to the reduction of the glomerular filtration rate[55]. Thromboxane A2 and angiotensin II cause contraction of the mesangial cells, decreasing the glomerular surface area that is used for filtration. After 2 d, increased thromboxane A2 reduces kidney plasma by 60%. With persistence of obstruction, more losses occur in the tubular brush epithelia and renal blood flow[56]. In addition, alterations in physiological sodium and water reabsorption are noted. Sodium absorption increases in the proximal tubules, but this increase is associated with a more significant decrease in sodium absorption in the juxtaglomerular nephrons. Furthermore, there is a reduction in the medullary ability to concentrate urine to only 350–400 mOsm[51,55,57]. This decrease in tonicity results in a drop in water absorption in the descending part of the loop of Henle. Metabolic acidosis and hyperkalemia are common in Po-AKI due to many factors, representing a failure of renal acidification. This occurs with the inability to excrete potassium and hydrogen, which is explained by distal renal tubular acidosis and Na-K-ATPase failure, resulting in hyperkalemia[51].

**Malignancy-based pathophysiological mechanisms:** There is a well-established relationship between malignancy and impairment of renal functions. These intimate relationships have led to the evolution of a new branch of nephrology that is concerned with associations of cancer with the renal diseases. It is not only malignancy that affects kidney function by ureteral obstruction, but also various nephropathies are associated with its hematopoietic, chemotherapeutic and immunotherapeutic effects of different types of malignancy. These nephropathies manifest clinically as proteinuria, hematuria, hypertension, and cancer related-chronic kidney disease[58-60].

AKI in patients with malignancy is relatively common. According to a study conducted on 37000 malignancy patients over a 5-year period, 27% of those patients developed AKI, and 7.6% of them developed severe AKI requiring dialysis. Also, the risk of AKI within the first year after a cancer diagnosis can be more than 18% in malignancy patients[51,61]. The non-obstructive causes of AKI in patients with malignancy include sepsis due to low immunity and bad general conditions, direct kidney injury due to the primary malignancy, metabolic disturbances, and nephrotoxic effects of chemotherapies. In turn, AKI increases the risk of toxic effects from systemic chemotherapy, threatening their continuation[62].

The development of ureteral obstruction in the course of any malignancy is considered a sign of disease progression and reduces the median survival to < 1 year[21,24,34]. MUO is a bad event that is usually associated with advanced, and often, incurable stages of malignancy. Further, it is a definitive cause of urosepsis, acute pain, and uremic syndrome. Unilateral or bilateral MUO is due to extrinsic compression or direct infiltration by a local primary tumor or retroperitoneal lymphadenopathy. It may occur in patients with a previously diagnosed malignancy up to 84%. The median patient age at MUO diagnosis is usually high (Table 1), and the median time for development of MUO after the diagnosis of primary malignancy is variable[5,23]. In comparison, the obstruction-based mechanisms seem to have a more favorable prognosis than the malignancy-based mechanisms. The effect of the benign mechanisms is usually unifactorial and reversible by a prompt drainage of the kidneys. In contrast, the malignancy-based mechanisms are virtually multifactorial and irreversible in most instances[62]. Hence, MUO is a modifiable risk factor of morbidity and mortality in patients with Po-AKI due to malignancy. Drainage of the obstructed kidneys can prevent the major sequelae of the obstruction-based mechanisms, promptly reversing the acute deteriorations of renal functions within days or weeks[5].

**CLINICAL PRESENTATION**

In Po-AKI, the clinical presentation includes the general manifestations of uremia and manifestations of urinary tract obstruction. The latter may include loin pain secondary to stretching of the urinary collecting system and hematuria caused by the obstructing malignancy[63]. Decrease in urine output is a common presentation, but it is not specific to Po-AKI[41,51]. Patients with Po-AKI may present with loin tenderness and fever when obstruction is associated with infection[51,57].

**DIAGNOSIS**

The initial laboratory evaluation should include measurement of blood gases and electrolyte levels, SCr, blood urea nitrogen, and complete blood count. Urinalysis may be requested in cases with a preserved urine output. Then, AKI could be diagnosed and staged according to KDIGO guidelines. In Po-AKI, the hallmark of diagnosis is the presence of hydronephrosis on abdominal ultrasonography (US) or computed tomography[41]. Hydronephrosis can easily be demonstrated by the grey scale US where pelvicalyceal dilatation is recognized with or without disappearance of the renal papillae[51]. After 3 to 4 wk of obstruction, diffuse thinning of the renal cortex and the medullary tissue is mostly recognizable. Moreover, Doppler US can evaluate the blood perfusion of the kidneys themselves by measuring the resistive index and ureteral obstruction by evaluation of the ureteral jets. The absence or decreased frequency of ureteral jets may indicate urinary obstruction. The severity of ureteric obstruction can be determined by evaluating all jet dynamics, including velocity, duration, and frequency[64]. However, computed tomography is still the most diagnostic tool of Po-AKI due to benign and malignant causes[5].

**MANAGEMENT**

***Initial measures of management***

While the management of the prerenal and renal types of AKI is mainly supportive in nature, drainage of BOKs is the cornerstone of management of Po-AKI. However, the initial conservative management of patients with Po-AKI is mostly similar to that of the other types. It consists of resuscitation and correction of the metabolic imbalances[41]. However, temporary drainage of BOKs is a mandatory and principal intervention, keeping the correction of the underlying cause to a time after recovery from AKI.

A urethral catheter placement can be performed in cases of bladder outlet obstruction such as benign prostatic hyperplasia, but PCN or double-J stent (JJ) are the usual methods in the cases of ureteral obstruction[2,4,65]. Then, the broad-line goals of management are to correct the biochemical abnormalities such as severe metabolic acidosis and hyperkalemia, prevent further injury or progression to chronic kidney disease, and treat the underlying pathology[65]. The management of hyperkalemia includes prevention of the life-threatening cardiac arrhythmias by administering calcium-based salts, support of shifting potassium into the cells, and enhancement of elimination of potassium through cation exchange resins[65,66].

Despite their fundamental roles, these pharmacological and conservative interventions may have a lower effect in the management of Po-AKI than in the management of the other types, relative to the role of drainage[51,57]. Renal replacement therapy is considered in specific circumstances, such as the progression of complications in the severe cases with pulmonary edema, persistent hyperkalemia, and disturbed consciousness. This therapy is mostly in the form of intermittent hemodialysis, but peritoneal dialysis may be performed in a few circumstances[41,51,67].

Regarding the practical aspect of prioritizing dialysis over drainage, there is a perspective that underscores whether the degree of elevation of SCr alone is an indicator to resort to dialysis before drainage[41]. It can be preferable to drain one or both kidneys whenever the patient can withstand the intervention for placement of a PCN[5]. This might augment the chances of recovery with the conservative management and in those patients who may still warrant temporary dialysis after drainage. Despite the drainage efficacy, dialysis could also play an important role in the management of those patients, especially when drainage is not preferable, such as in patients with a very poor prognosis[52,68].

***Drainage of BOKs***

Currently, there is no consensus or well-established guidelines addressing the proper drainage of MUO, leading to wide variations in the practice patterns and preferences[5,69,70]. However, relieving MUO prevents death from progressive renal failure and possibly prolongs the patient survival[20,24]. There are two modalities for drainage of the kidneys with MUO: PCN and JJ. Both methods can cause considerable morbidity and reduce a patient’s health–related QoL. There are multiple studies that compared both of them and their impact on QoL in MUO because those patients are usually in late stages and their QoL is already impaired[9,71]. The use of JJ for drainage of BOKs has many challenges, including higher invasiveness, need of anesthesia, liability of obstruction, and impossible placement due to complete obliteration of the ureteral lumen. These limitations are potentially present with antegrade and retrograde placement[72,73]. These challenges led to the development of the JJ characteristics, ranging from the new materials to the pressure-based capabilities. JJ has different types, ranging from the conventional polymeric stents to the malignancy-specifically designed stents. Among the latter, there are 3 important types that have gained popularity in recent years and are used in MUO: tandem ureteric stent; metallic stent; and metal-mesh ureteral stents. Many studies have concluded very high rates of stent failure in MUO because the tumor or lymphadenopathy compresses the ureter against the indwelling stent, persistently obliterating the tube lumen and limiting the extraluminal flow[74,75]. Also, the ureteral stent promotes mucous production from the urothelium and leads to urothelial sloughing. The lumen of a ureteral stent can become occluded with this debris[76-78].

Metallic ureteral stents gained superiority over the conventional JJ as they have a low occlusion rate, high success rate (60%) at 1 year, and low failure rate (15.4%)[79]. Considering that the median survival time with extrinsic MUO is about 1 year[24,34], there is a high possibility that metallic stent replacement is unnecessary during a patient’s life. Tandem ureteric stent consists of a side-by-side ureteric stents within the ureter and can resist obstruction by providing a space in between the two stents that is difficult to compress. It has a success rate of approximately 87% at 2 years[80]. It has a range of exchange from 6 mo to 1 year[76,80]. Success rates ranged from 88% for the Allium stent to 65% for the Memokath 051. Resonance stent demonstrated the lowest migration rate (1%). Uventa showed the lowest obstruction rate (6%). A comparative study conducted by Chen *et al*[81] reported that metallic stents have longer indwelling time and are superior to conventional polymeric stents. There is a mean increase in functional duration of 4 mo, using the Resonance stent when it is compared to conventional polymeric stent[75].

Although PCN has a high success rate[13] and is considered safer than JJ[69], its need to carry an external bag could threaten the patient QoL[69]. PCN seems to be more suitable for patients with advanced malignancy who may not have the candidacy for anesthesia or the ureteral patency to pass JJ. Also, they may have expected survival rates less than 12 mo that could be improved by PCN. However, the disturbance of their QoL is still the main concern, warranting estimation of the balance between the benefits and the risks[6,70]. There are no clear advantages between the two forms of urinary diversion in MUO[6] (Tables 1 and 2). However, the type of urinary diversion depends on the experience of the urologist, the existing expertise, the availability of the armamentarium, the stage of malignancy, and the urgency of the diversion[82]. In addition, it is dependent on the potential benefits of diversion at different parameters, including the radiological exposure, decrease in SCr, the overall complication rate, febrile episodes after drainage, tube exchange rate, and overall patient survival. Both drainage forms seem to have no advantage over each other in these variables[43].

However, despite the evidence-based recommendation by the recent meta-analyses in favor of the use of JJ rather than PCN in patients with MUO[43], there is an attitude that PCN is more commonly used than JJ for drainage of BOKS with MUO (Table 1). This attitude is noticeable in the single-center studies[5,8,83]. Owing to the potential of placement of wide-caliber tubes and insertion of antegrade JJ[11,37], PCN may provide the chance of obtaining high drainage capacities[44]. Also, PCN may become the only suitable method for drainage, especially in the elderly patients with advanced stages of malignancy who are not candidates for intervention[34,43], or have non-passable MUO[15,43]. On the other hand, PCN may disturb the QoL more than JJ[6,19]. This may be attributable to many potential unfavorable events with PCN such as the repeated slippage, obstruction, and urinary leakage. Hence, there should be a sufficient rationale to perform urinary diversion by PCN in patients with terminal stages of malignancy[6,57,84]. If the evidence of the effect on QoL is absent, the potential survival benefit remains the individual factor that drives the decision, which should be PCN in patients with advanced malignancy[43,84]. This may be attributed to the fact that most of these patients have no further oncological treatment chances following the diversion[39].

Laterality of drainage of BOKs with MUO has been addressed by some authors like Hyppolite *et al*[85] who concluded superiority of bilateral over unilateral drainage. However, Nariculam *et al*[28] found no difference between unilateral and bilateral drainage. The combination of the tool and side of drainage in cases of BOKs is known as the mode of drainage. Despite the continuous research, the definition of the optimal mode of drainage of BOKs is still controversial, including the cases of MUO[5,43,70]. We may adopt the perspective of performing unilateral drainage of BOKs, unless there are bilateral infections, pain, or non-improvement of SCr after unilateral drainage. In the latter situation, bilateral drainage can be performed consecutively[5]. Similarly, the optimal mode of drainage of BOKs due to BUO is still controversial. In a recent survey study to evaluate the preferences of urologists and radiologists who may have the principal duties of interventions in cases of acute BOKs, the conclusion was to individualize the decision for each case with emergency indications for upper tract decompression by JJ *vs* PCN[86].

**PROGNOSTIC PARAMETERS AFTER DRAINAGE OF BOKs DUE TO MUO**

***Urine output***

An increase in urine output is an early sign of renal recovery in patients with oliguric AKI. This is accompanied by a reduction in the level of high SCr, followed by a plateau period, and a subsequent fall in SCr[8,54]. Usually, the increase of urine output is physiologic and self-limiting within the first 24 h after relief of obstruction. The kidneys try to normalize the internal environment of the body by fluid and electrolyte homeostasis within the early hours before returning to the normal status of the urine output[57]. The post-obstructive diuresis means increased urine output after relief of BOKs. It is defined as increased urine output > 200 mL for two consecutive hours or urine output > 3000 mL per 24 h after relief of obstruction. When this diuresis becomes excessive or is prolonged, it becomes pathologic. It is attributed to the sudden release of the obstruction, which initiates reflex diuresis by multiple mechanisms, evoking the full capacity of the functioning nephrons[57].

There is a perspective that post-obstructive diuresis may be a sign of the acuteness of the condition and the magnitude of the renal power preserved. Also, it is believed that it is more common after drainage of BOKs due to BUO than those due to MUO[5]. For example, an obstruction by a stone is related to its migratory potential that can be sudden and complete in comparison with an infiltrating malignancy that causes a gradual obstruction[6,7]. However, this point of difference between BUO and MUO has not been sufficiently addressed in the literature. Despite its favorable prognostic values, the potential pathologic, metabolic, and circulatory risks of post-obstructive diuresis may threaten the patient’s life. Hence, it should be managed properly by oral or intravenous fluid compensation and management of the electrolyte imbalances that could ensue with excessive diuresis[57].

***SCr trajectory***

The rate of change of SCr over time in AKI is known as the creatinine trajectory. It can be applied in both the deterioration and recovery phases[1,5]. The time factor in this topic reflects its practical importance in catching a cure in patients with MUO. SCr trajectory has attracted the attention in the management of patients with prerenal and renal AKI[87]. However, it is still not recognizable in cases of Po-AKI. Our own work on this subject has not been published yet. The SCr trajectory is a potential parameter to understand AKI during both the renal dysfunction and recovery phases. The deterioration SCr trajectory may facilitate clinical classification and subtyping of AKI, using a different parameter rather than maximal SCr change. However, it mandates knowing a predeterioration or baseline SCr level, which is often lacking for most patients admitted in an emergency setting[1,88]. On the other hand, based on SCr trajectory, the post-intervention classification facilitates understanding patient responses to early medical interventions. This could be provided by serial measures of SCr. Hence, the identification of AKI subclasses based on SCr trajectory has been proposed as a tool to improve the precision of risk stratification of patients with AKI[1,87,88].

***The time-to-nadir SCr***

The time needed to reach a nadir SCr or what is known as the time-to-nadir SCr after drainage of BOKs is another parameter of the responses of the kidneys to drainage. To the best of our knowledge, this parameter has not been sufficiently addressed in the literature of Po-AKI due to MUO. However, our work in this issue has revealed that large proportions of patients may fail to reach a normal nadir SCr due to the burden of malignancy. Also, the time-to-nadir in cases of MUO seems to be longer than that in the cases of BUO[5]. Furthermore, the long time-to-nadir SCr may be associated with a low predrainage urine output and high body mass index. The rationale of measurement of the time-to-nadir SCr in patients with AKI is related to the magnitudes of benefits provided by early recovery, regarding the chance of cure or early management. This issue is still controversial in patients with MUO. The time-to-nadir SCr may be significantly shorter in patients with the potential to normalize SCr than in patients without normalized SCr levels after drainage[89].

***Malignancy-related factors***

The literature reports that some malignancies are statistically significant predictors of worse survival (Table 1). They include the unresectable or unsuitable malignancies for chemotherapy[83], gastropancreatic[90], hormonal-resistant prostate cancers, and those requiring hemodialysis before the procedure[16]. Despite the successful drainage of BOKs in cases of MUO, the survival rate is still poor[23]. The three significant factors that can predict a short survival time after PCN in patients with advanced stage malignancy are a low serum albumin before placement of PCN (3 g/dL or less), low grade hydronephrosis (Grade 1 or 2), and a large number of events related to malignant dissemination (3 or more). Patients who had only one variable had a 69% chance of 6-mo survival, those who had two variables had a 24% survival rate, and those with three variables had a 2% survival rate[6,26]. Wong *et al*[23] identified other predictors as metastases, prior therapy, and diagnosis of MUO with a previously established malignancy. Despite developing these prognostic models, there should be a shared decision-making approach to perform invasive procedures like PCN and JJ, with a questionable degree of the effect on renal function recovery and the risk of complications. There should be a proper explanation of prognosis, subsequent treatment possibilities, and expected results before proceeding to these invasive maneuvers[42].

***Current perspectives and future expectations to improve the poor prognosis***

In the last decade, the literature has shown an extensive study of the predictors of the success and overall survival rates in patients with MUO. The common finding in this category of patients is the poor overall survival with advanced MUO[68,91]. Many directions have been adopted in research to define the modifiable factors affecting the outcomes of drainage of BOKs in those patients. The main direction is studying the factors related to obstruction-based sequelae of MUO. Besides the type of malignancy, the occurrence of MUO and its degree and laterality were included as risk factors[92,93]. Electrolytes and blood biochemical compounds such as serum albumin and hemoglobin levels have been found as independent factors[94,95]. Hence, several prognostic models have been configured and published, initiating more debates on the optimal management approach[96-99]. As an overview, the ongoing fact that seems to be verified with time is that not all patients gain benefits from drainage, and treatment should be individualized to each patient[95,100]. Another direction is the improvement of the qualities and compression-bearing capabilities of the drainage tools, represented by the advances in manufacturing of JJ for MUO. In addition, the research has gone to outweighing the certainty of the benefits of interventions versus observation in those patients, considering disturbances of QoL as a principal factor in decision-making[101,102].

**CONCLUSION**

AKI due to MUO is a urological emergency, warranting immediate evaluation and management. The principal line of treatment is the drainage of the kidneys *via* a placement of PCN or JJ. Despite the growing relevant literature, there is no consensus on the optimal approach. Several prognostic models have been attempted to stratify those patients relative to the potential risks and justify the interventions, but the controversies persist. Hence, the decision-making should be tailored to the patient stage and status rather than to strict guidelines. This selective approach may be attributed to the presence of many prognostic factors that should be considered during management, including the QoL and the anticipated benefit of drainage with a markedly reduced life expectancy of those patients.

**REFERENCES**

1 **Bhatraju PK**, Mukherjee P, Robinson-Cohen C, O'Keefe GE, Frank AJ, Christie JD, Meyer NJ, Liu KD, Matthay MA, Calfee CS, Christiani DC, Himmelfarb J, Wurfel MM. Acute kidney injury subphenotypes based on creatinine trajectory identifies patients at increased risk of death. *Crit Care* 2016; **20**: 372 [PMID: 27852290 DOI: 10.1186/s13054-016-1546-4]

2 Section 2: AKI Definition. *Kidney Int Suppl (2011)* 2012; **2**: 19-36 [PMID: 25018918 DOI: 10.1038/kisup.2011.32]

3 **Bellomo R**, Kellum JA, Ronco C. Acute kidney injury. *Lancet* 2012; **380**: 756-766 [PMID: 22617274 DOI: 10.1016/S0140-6736(11)61454-2]

4 **Farrar A**. Acute Kidney Injury. *Nurs Clin North Am* 2018; **53**: 499-510 [PMID: 30388976 DOI: 10.1016/j.cnur.2018.07.001]

5 **Gadelkareem RA**, Abdelraouf AM, El-Taher AM, Ahmed AI, Mohammed N. Predictors of nadir serum creatinine after drainage of bilaterally obstructed kidneys due to different etiologies. *Int Urol Nephrol* 2022; **54**: 2105-2116 [PMID: 35794400 DOI: 10.1007/s11255-022-03278-2]

6 **New FJ**, Deverill SJ, Somani BK. Outcomes Related to Percutaneous Nephrostomies (PCN) in Malignancy-Associated Ureteric Obstruction: A Systematic Review of the Literature. *J Clin Med* 2021; **10** [PMID: 34072127 DOI: 10.3390/jcm10112354]

7 **Weltings S**, Schout BMA, Roshani H, Kamphuis GM, Pelger RCM. Lessons from Literature: Nephrostomy Versus Double J Ureteral Catheterization in Patients with Obstructive Urolithiasis-Which Method Is Superior? *J Endourol* 2019; **33**: 777-786 [PMID: 31250680 DOI: 10.1089/end.2019.0309]

8 **Haas CR**, Shah O, Hyams ES. Temporal Trends and Practice Patterns for Inpatient Management of Malignant Extrinsic Ureteral Obstruction in the United States. *J Endourol* 2020; **34**: 828-835 [PMID: 32340482 DOI: 10.1089/end.2020.0053]

9 **Pappas P**, Stravodimos KG, Mitropoulos D, Kontopoulou C, Haramoglis S, Giannopoulou M, Tzortzis G, Giannopoulos A. Role of percutaneous urinary diversion in malignant and benign obstructive uropathy. *J Endourol* 2000; **14**: 401-405 [PMID: 10958560 DOI: 10.1089/end.2000.14.401]

10 **Ekici S**, Sahin A, Ozen H. Percutaneous nephrostomy in the management of malignant ureteral obstruction secondary to bladder cancer. *J Endourol* 2001; **15**: 827-829 [PMID: 11724123 DOI: 10.1089/089277901753205834]

11 **Chitale SV**, Scott-Barrett S, Ho ET, Burgess NA. The management of ureteric obstruction secondary to malignant pelvic disease. *Clin Radiol* 2002; **57**: 1118-1121 [PMID: 12475538 DOI: 10.1053/crad.2002.1114]

12 **Chung SY**, Stein RJ, Landsittel D, Davies BJ, Cuellar DC, Hrebinko RL, Tarin T, Averch TD. 15-year experience with the management of extrinsic ureteral obstruction with indwelling ureteral stents. *J Urol* 2004; **172**: 592-595 [PMID: 15247739 DOI: 10.1097/01.ju.0000130510.28768.f5]

13 **Ku JH,** Lee SW, Jeon HG, Kim HH, Oh SJ. Percutaneous nephrostomy vs indwelling ureteral stents in the management of extrinsic ureteral obstruction in advanced malignancies: are there differences? Urology 2004; 64: 895-899 [DOI:10.1016/j.urology.2004.06.029]

14 **Danilovic A**, Antonopoulos IM, Mesquita JL, Lucon AM. Likelihood of retrograde double-J stenting according to ureteral obstructing pathology. *Int Braz J Urol* 2005; **31**: 431-6; discussion 436 [PMID: 16255788 DOI: 10.1590/s1677-55382005000500003]

15 **Ganatra AM**, Loughlin KR. The management of malignant ureteral obstruction treated with ureteral stents. *J Urol* 2005; **174**: 2125-2128 [PMID: 16280741 DOI: 10.1097/01.ju.0000181807.56114.b7]

16 **Romero FR**, Broglio M, Pires SR, Roca RF, Guibu IA, Perez MD. Indications for percutaneous nephrostomy in patients with obstructive uropathy due to malignant urogenital neoplasias. *Int Braz J Urol* 2005; **31**: 117-124 [PMID: 15877830 DOI: 10.1590/s1677-55382005000200005]

17 **Rosenberg BH**, Bianco FJ Jr, Wood DP Jr, Triest JA. Stent-change therapy in advanced malignancies with ureteral obstruction. *J Endourol* 2005; **19**: 63-67 [PMID: 15735386 DOI: 10.1089/end.2005.19.63]

18 **Uthappa MC**, Cowan NC. Retrograde or antegrade double-pigtail stent placement for malignant ureteric obstruction? *Clin Radiol* 2005; **60**: 608-612 [PMID: 15851050 DOI: 10.1016/j.crad.2004.11.014]

19 **Wilson JR**, Urwin GH, Stower MJ. The role of percutaneous nephrostomy in malignant ureteric obstruction. *Ann R Coll Surg Engl* 2005; **87**: 21-24 [PMID: 15720902 DOI: 10.1308/1478708051432]

20 **Radecka E**, Magnusson M, Magnusson A. Survival time and period of catheterization in patients treated with percutaneous nephrostomy for urinary obstruction due to malignancy. *Acta Radiol* 2006; **47**: 328-331 [PMID: 16613316 DOI: 10.1080/02841850500492092]

21 **Kanou T**, Fujiyama C, Nishimura K, Tokuda Y, Uozumi J, Masaki Z. Management of extrinsic malignant ureteral obstruction with urinary diversion. *Int J Urol* 2007; **14**: 689-692 [PMID: 17681056 DOI: 10.1111/j.1442-2042.2007.01747.x]

22 **Rosevear HM**, Kim SP, Wenzler DL, Faerber GJ, Roberts WW, Wolf JS Jr. Retrograde ureteral stents for extrinsic ureteral obstruction: nine years' experience at University of Michigan. *Urology* 2007; **70**: 846-850 [PMID: 18068437 DOI: 10.1016/j.urology.2007.07.008]

23 **Wong LM**, Cleeve LK, Milner AD, Pitman AG. Malignant ureteral obstruction: outcomes after intervention. Have things changed? *J Urol* 2007; **178**: 178-83; discussion 183 [PMID: 17499300 DOI: 10.1016/j.juro.2007.03.026]

24 **Ishioka J**, Kageyama Y, Inoue M, Higashi Y, Kihara K. Prognostic model for predicting survival after palliative urinary diversion for ureteral obstruction: analysis of 140 cases. *J Urol* 2008; **180**: 618-21; discussion 621 [PMID: 18554655 DOI: 10.1016/j.juro.2008.04.011]

25 **McCullough TC**, May NR, Metro MJ, Ginsberg PC, Jaffe JS, Harkaway RC. Serum creatinine predicts success in retrograde ureteral stent placement in patients with pelvic malignancies. *Urology* 2008; **72**: 370-373 [PMID: 18336878 DOI: 10.1016/j.urology.2007.12.068]

26 **Lienert A**, Ing A, Mark S. Prognostic factors in malignant ureteric obstruction. *BJU Int* 2009; **104**: 938-941 [PMID: 19338533 DOI: 10.1111/j.1464-410X.2009.08492.x]

27 **Mishra K**, Desai A, Patel S, Mankad M, Dave K. Role of percutaneous nephrostomy in advanced cervical carcinoma with obstructive uropathy: a case series. *Indian J Palliat Care* 2009; **15**: 37-40 [PMID: 20606854 DOI: 10.4103/0973-1075.53510]

28 **Nariculam J**, Murphy DG, Jenner C, Sellars N, Gwyther S, Gordon SG, Swinn MJ. Nephrostomy insertion for patients with bilateral ureteric obstruction caused by prostate cancer. *Br J Radiol* 2009; **82**: 571-576 [PMID: 19153185 DOI: 10.1259/bjr/38306763]

29 **Jalbani MH**, Deenari RA, Dholia KR, Oad AK, Arbani IA. Role of percutaneous nephrostomy (PCN) in malignant ureteral obstruction. *J Pak Med Assoc* 2010; **60**: 280-283 [PMID: 20419970]

30 **Kamiyama Y**, Matsuura S, Kato M, Abe Y, Takyu S, Yoshikawa K, Arai Y. Stent failure in the management of malignant extrinsic ureteral obstruction: risk factors. *Int J Urol* 2011; **18**: 379-382 [PMID: 21518020 DOI: 10.1111/j.1442-2042.2011.02731.x]

31 **Migita K**, Watanabe A, Samma S, Ohyama T, Ishikawa H, Kagebayashi Y. Clinical outcome and management of ureteral obstruction secondary to gastric cancer. *World J Surg* 2011; **35**: 1035-1041 [PMID: 21387134 DOI: 10.1007/s00268-011-1016-8]

32 **Song Y,** Fei X, Song Y. Percutaneous nephrostomy vs indwelling ureteral stent in the management of gynecological malignancies. Int J Gynecol Cancer 2012; 22: 697-702 [DOI:10.1097/igc.0b013e318243b475]

33 **Misra S**, Coker C, Richenberg J. Percutaneous nephrostomy for ureteric obstruction due to advanced pelvic malignancy: have we got the balance right? *Int Urol Nephrol* 2013; **45**: 627-632 [PMID: 23666587 DOI: 10.1007/s11255-013-0458-3]

34 **Cordeiro MD**, Coelho RF, Chade DC, Pessoa RR, Chaib MS, Colombo-Júnior JR, Pontes-Júnior J, Guglielmetti GB, Srougi M. A prognostic model for survival after palliative urinary diversion for malignant ureteric obstruction: a prospective study of 208 patients. *BJU Int* 2016; **117**: 266-271 [PMID: 25327474 DOI: 10.1111/bju.12963]

35 **Efesoy O**, Saylam B, Bozlu M, Çayan S, Akbay E. The results of ultrasound-guided percutaneous nephrostomy tube placement for obstructive uropathy: A single-centre 10-year experience. *Turk J Urol* 2018; **44**: 329-334 [PMID: 29799408 DOI: 10.5152/tud.2018.25205]

36 **Tan S**, Tao Z, Bian X, Zhao Y, Wang N, Chen X, Wu B. Ureteral stent placement and percutaneous nephrostomy in the management of hydronephrosis secondary to cervical cancer. *Eur J Obstet Gynecol Reprod Biol* 2019; **241**: 99-103 [PMID: 31484100 DOI: 10.1016/j.ejogrb.2019.08.020]

37 **Tibana TK**, Grubert RM, Santos RFT, Fornazari VAV, Domingos AA, Reis WT, Marchiori E, Nunes TF. Percutaneous nephrostomy versus antegrade double-J stent placement in the treatment of malignant obstructive uropathy: a cost-effectiveness analysis from the perspective of the Brazilian public health care system. *Radiol Bras* 2019; **52**: 305-311 [PMID: 31656347 DOI: 10.1590/0100-3984.2018.0127]

38 **De Lorenzis E,** Lievore E, Turetti M, Gallioli A, Galassi B, Boeri L, Montanari E. Ureteral stent and percutaneous nephrostomy in managing malignant ureteric obstruction of gastrointestinal origin: A 10 years’ experience. GastrointestDisord 2020;2: 456-468 [DOI:10.3390/gidisord2040041]

39 **Folkard SS,** Banerjee S, Menzies-Wilson R, Reason J, Psallidas E, Clissold E, Al-Mushatat A, Chaudhri S, Green JSA. Percutaneous nephrostomy in obstructing pelvic malignancy does not facilitate further oncological treatment. IntUrolNephrol 2020; 52: 1625-1628 [DOI:10.1007/s11255-020-02466-2]

40 **Izumi K**, Shima T, Shigehara K, Sawada K, Naito R, Kato Y, Ofude M, Kano H, Iwamoto H, Yaegashi H, Nakashima K, Iijima M, Kawaguchi S, Nohara T, Kadono Y, Mizokami A. A novel risk classification score for malignant ureteral obstruction: a multicenter prospective validation study. *Sci Rep* 2021; **11**: 4455 [PMID: 33627826 DOI: 10.1038/s41598-021-84054-7]

41 **Kbirou A**, Sayah M, Sounni F, Zamd M, Benghanem MG, Dakir M, Debbagh A, Aboutaib R. Obstructive oligo-anuria revealing pelvic gynecological cancers, analysis of a series of 102 cases. *Ann Med Surg (Lond)* 2022; **75**: 103332 [PMID: 35198181 DOI: 10.1016/j.amsu.2022.103332]

42 **Pickersgill NA**, Wahba BM, Vetter JM, Cope SJ, Barashi NS, Henning GM, Du K, Figenshau RS, Desai AC, Venkatesh R. Factors Associated with Ureteral Stent Failure in Patients with Malignant Ureteral Obstruction. *J Endourol* 2022; **36**: 814-818 [PMID: 35018790 DOI: 10.1089/end.2021.0364]

43 **Gauhar V,** Pirola GM, Scarcella S, De Angelis MV, Giulioni C, Rubilotta E, Gubbiotti M, Lim EJ, Law YXT, Wroclawski ML, Tiong HY, Castellani D. Nephrostomy tube vs double J ureteral stent in patients with malignant ureteric obstruction. A systematic review and meta-analysis of comparative studies.IntBraz J Urol 2022; 48: 903-914 [DOI:10.1016/s0302-2838(22)00267-6]

44 **Sountoulides P**, Mykoniatis I, Dimasis N. Palliative management of malignant upper urinary tract obstruction. *Hippokratia* 2014; **18**: 292-297 [PMID: 26052193]

45 **Ftouh S**, Thomas M; Acute Kidney Injury Guideline Development Group. Acute kidney injury: summary of NICE guidance. *BMJ* 2013; **347**: f4930 [PMID: 23985310 DOI: 10.1136/bmj.f4930]

46 **Chawla LS**, Amdur RL, Amodeo S, Kimmel PL, Palant CE. The severity of acute kidney injury predicts progression to chronic kidney disease. *Kidney Int* 2011; **79**: 1361-1369 [PMID: 21430640 DOI: 10.1038/ki.2011.42]

47 **Lewington AJ**, Cerdá J, Mehta RL. Raising awareness of acute kidney injury: a global perspective of a silent killer. *Kidney Int* 2013; **84**: 457-467 [PMID: 23636171 DOI: 10.1038/ki.2013.153]

48 **Lameire NH**, Bagga A, Cruz D, De Maeseneer J, Endre Z, Kellum JA, Liu KD, Mehta RL, Pannu N, Van Biesen W, Vanholder R. Acute kidney injury: an increasing global concern. *Lancet* 2013; **382**: 170-179 [PMID: 23727171 DOI: 10.1016/S0140-6736(13)60647-9]

49 **Hamdi A**, Hajage D, Van Glabeke E, Belenfant X, Vincent F, Gonzalez F, Ciroldi M, Obadia E, Chelha R, Pallot JL, Das V. Severe post-renal acute kidney injury, post-obstructive diuresis and renal recovery. *BJU Int* 2012; **110**: E1027-E1034 [PMID: 22583774 DOI: 10.1111/j.1464-410X.2012.11193.x]

50 **Akposso K**, Hertig A, Couprie R, Flahaut A, Alberti C, Karras GA, Haymann JP, Costa De Beauregard MA, Lahlou A, Rondeau E, Sraer JD. Acute renal failure in patients over 80 years old: 25-years' experience. *Intensive Care Med* 2000; **26**: 400-406 [PMID: 10872131 DOI: 10.1007/s001340051173]

51 **Chávez-Iñiguez JS**, Navarro-Gallardo GJ, Medina-González R, Alcantar-Vallin L, García-García G. Acute Kidney Injury Caused by Obstructive Nephropathy. *Int J Nephrol* 2020; **2020**: 8846622 [PMID: 33312728 DOI: 10.1155/2020/8846622]

52 **Garg G**, Bansal N, Singh M, Sankhwar SN. Role of Percutaneous Nephrostomy in Bladder Carcinoma with Obstructive Uropathy: A Story Revisited. *Indian J Palliat Care* 2019; **25**: 53-56 [PMID: 30820102 DOI: 10.4103/IJPC.IJPC\_102\_18]

53 **Ostermann M**, Liu K. Pathophysiology of AKI. *Best Pract Res Clin Anaesthesiol* 2017; **31**: 305-314 [PMID: 29248138 DOI: 10.1016/j.bpa.2017.09.001]

54 **Anathhanam S**, Lewington AJ. Acute kidney injury. *J R Coll Physicians Edinb* 2013; **43**: 323-8; quiz 329 [PMID: 24350317 DOI: 10.4997/JRCPE.2013.412]

55 **Hammad FT**. The long-term renal effects of short periods of unilateral ureteral obstruction. *Int J Physiol Pathophysiol Pharmacol* 2022; **14**: 60-72 [PMID: 35619661]

56 **Nagalakshmi VK**, Li M, Shah S, Gigliotti JC, Klibanov AL, Epstein FH, Chevalier RL, Gomez RA, Sequeira-Lopez MLS. Changes in cell fate determine the regenerative and functional capacity of the developing kidney before and after release of obstruction. *Clin Sci (Lond)* 2018; **132**: 2519-2545 [PMID: 30442812 DOI: 10.1042/CS20180623]

57 **Harrison S,** Lasri A, Jabbour Y, Slaoui A, Djamal J, Karmouni T, Khader KE, Koutani A, Andaloussi AIA. Post-Obstructive Diuresis: Physiopathology, Diagnosis and Management after Urological Treatment of Obstructive Renal Failure. Open J Urol 2018; **8**:267-274 [DOI:10.4236/oju.2018.89030]

58 **Leung N**, Bridoux F, Batuman V, Chaidos A, Cockwell P, D'Agati VD, Dispenzieri A, Fervenza FC, Fermand JP, Gibbs S, Gillmore JD, Herrera GA, Jaccard A, Jevremovic D, Kastritis E, Kukreti V, Kyle RA, Lachmann HJ, Larsen CP, Ludwig H, Markowitz GS, Merlini G, Mollee P, Picken MM, Rajkumar VS, Royal V, Sanders PW, Sethi S, Venner CP, Voorhees PM, Wechalekar AD, Weiss BM, Nasr SH. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. *Nat Rev Nephrol* 2019; **15**: 45-59 [PMID: 30510265 DOI: 10.1038/s41581-018-0077-4]

59 **Rosner MH**, Jhaveri KD, McMahon BA, Perazella MA. Onconephrology: The intersections between the kidney and cancer. *CA Cancer J Clin* 2021; **71**: 47-77 [PMID: 32853404 DOI: 10.3322/caac.21636]

60 **Perazella MA**. Onco-nephrology: renal toxicities of chemotherapeutic agents. *Clin J Am Soc Nephrol* 2012; **7**: 1713-1721 [PMID: 22879440 DOI: 10.2215/CJN.02780312]

61 **Christiansen CF**, Johansen MB, Langeberg WJ, Fryzek JP, Sørensen HT. Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study. *Eur J Intern Med* 2011; **22**: 399-406 [PMID: 21767759 DOI: 10.1016/j.ejim.2011.05.005]

62 **Rosner MH**, Perazella MA. Acute Kidney Injury in Patients with Cancer. *N Engl J Med* 2017; **376**: 1770-1781 [PMID: 28467867 DOI: 10.1056/NEJMra1613984]

63 **Bultitude M**, Rees J. Management of renal colic. *BMJ* 2012; **345**: e5499 [PMID: 22932919 DOI: 10.1136/bmj.e5499]

64 **Hassan W**, Sharif I, El Khalid S, Ellahibux K, Sultan S, Waqar A, Zohaib A, Yousuf F. Doppler-Assessed Ureteric Jet Frequency: A Valuable Predictor of Ureteric Obstruction. *Cureus* 2021; **13**: e18290 [PMID: 34722066 DOI: 10.7759/cureus.18290]

65 **Moore PK**, Hsu RK, Liu KD. Management of Acute Kidney Injury: Core Curriculum 2018. *Am J Kidney Dis* 2018; **72**: 136-148 [PMID: 29478864 DOI: 10.1053/j.ajkd.2017.11.021]

66 **Nyirenda MJ**, Tang JI, Padfield PL, Seckl JR. Hyperkalaemia. *BMJ* 2009; **339**: b4114 [PMID: 19854840 DOI: 10.1136/bmj.b4114]

67 **Pannu N**, Klarenbach S, Wiebe N, Manns B, Tonelli M; Alberta Kidney Disease Network. Renal replacement therapy in patients with acute renal failure: a systematic review. *JAMA* 2008; **299**: 793-805 [PMID: 18285591 DOI: 10.1001/jama.299.7.793]

68 **Heo JE**, Jeon DY, Lee J, Ham WS, Choi YD, Jang WS. Clinical Outcomes After Urinary Diversion for Malignant Ureteral Obstruction Secondary to Non-urologic Cancer: An Analysis of 778 Cases. *Ann Surg Oncol* 2021; **28**: 2367-2373 [PMID: 33389298 DOI: 10.1245/s10434-020-09423-4]

69 **Hsu L**, Li H, Pucheril D, Hansen M, Littleton R, Peabody J, Sammon J. Use of percutaneous nephrostomy and ureteral stenting in management of ureteral obstruction. *World J Nephrol* 2016; **5**: 172-181 [PMID: 26981442 DOI: 10.5527/wjn.v5.i2.172]

70 **O'Connor EM**, Nason GJ, Kiely EA. Urological Management of Extramural Malignant Ureteric Obstruction: A Survey of Irish Urologists. *Curr Urol* 2017; **11**: 21-25 [PMID: 29463973 DOI: 10.1159/000447190]

71 **Shoshany O,** Erlich T, Golan S, Kleinmann N, Baniel J, Rosenzweig B, Eisner A, Mor Y, Ramon J, Winkler H, Lifshitz D. Ureteric stent vs percutaneous nephrostomy for acute ureteral obstruction - clinical outcome and quality of life: a bi-center prospective study. BMC Urol 2019; 19: 79 [DOI:10.1186/s12894-019-0510-4]

72 **Tlili G**, Ammar H, Dziri S, Ben Ahmed K, Farhat W, Arem S, Acacha E, Gupta R, Rguez A, Jaidane M. Antegrade double-J stent placement for the treatment of malignant obstructive uropathy: A retrospective cohort study. *Ann Med Surg (Lond)* 2021; **69**: 102726 [PMID: 34466220 DOI: 10.1016/j.amsu.2021.102726]

73 **Fabiano de Oliveira Leite T**, Vatanabe Pazinato L, Mauricio da Motta Leal Filho J. Percutaneous insertion of bilateral double J in pelvic cancer patients: Indications, complications, technique of antegrade ureteral stenting. *Gynecol Oncol Rep* 2021; **38**: 100864 [PMID: 34926753 DOI: 10.1016/j.gore.2021.100864]

74 **Asakawa J**, Iguchi T, Tamada S, Ninomiya N, Kato M, Yamasaki T, Nakatani T. Treatment outcomes of ureteral stenting for malignant extrinsic ureteral obstruction: a comparison between polymeric and metallic stents. *Cancer Manag Res* 2018; **10**: 2977-2982 [PMID: 30214292 DOI: 10.2147/CMAR.S172283]

75 **Chow PM**, Chiang IN, Chen CY, Huang KH, Hsu JS, Wang SM, Lee YJ, Yu HJ, Pu YS, Huang CY. Malignant Ureteral Obstruction: Functional Duration of Metallic versus Polymeric Ureteral Stents. *PLoS One* 2015; **10**: e0135566 [PMID: 26267140 DOI: 10.1371/journal.pone.0135566]

76 **Elsamra SE**, Leavitt DA, Motato HA, Friedlander JI, Siev M, Keheila M, Hoenig DM, Smith AD, Okeke Z. Stenting for malignant ureteral obstruction: Tandem, metal or metal-mesh stents. *Int J Urol* 2015; **22**: 629-636 [PMID: 25950837 DOI: 10.1111/iju.12795]

77 **Goldsmith ZG**, Wang AJ, Bañez LL, Lipkin ME, Ferrandino MN, Preminger GM, Inman BA. Outcomes of metallic stents for malignant ureteral obstruction. *J Urol* 2012; **188**: 851-855 [PMID: 22819410 DOI: 10.1016/j.juro.2012.04.113]

78 **Nagele U**, Kuczyk MA, Horstmann M, Hennenlotter J, Sievert KD, Schilling D, Walcher U, Stenzl A, Anastasiadis AG. Initial clinical experience with full-length metal ureteral stents for obstructive ureteral stenosis. *World J Urol* 2008; **26**: 257-262 [PMID: 18324407 DOI: 10.1007/s00345-008-0245-4]

79 **Asakawa J**, Iguchi T, Tamada S, Ninomiya N, Kato M, Yamasaki T, Nakatani T. Outcomes of indwelling metallic stents for malignant extrinsic ureteral obstruction. *Int J Urol* 2018; **25**: 258-262 [PMID: 29194771 DOI: 10.1111/iju.13500]

80 **Elsamra SE**, Motato H, Moreira DM, Waingankar N, Friedlander JI, Weiss G, Smith AD, Okeke Z. Tandem ureteral stents for the decompression of malignant and benign obstructive uropathy. *J Endourol* 2013; **27**: 1297-1302 [PMID: 23829600 DOI: 10.1089/end.2013.0281]

81 **Chen Y,** Liu CY, Zhang ZH, Xu PC, Chen DG, Fan XH, Ma JC, Xu YP. Malignant ureteral obstruction: experience and comparative analysis of metallic vs ordinary polymer ureteral stents. World J SurgOncol 2019; 17: 74 [DOI:10.1186/s12957-019-1608-6]

82 **Hyams ES**, Shah O. Malignant extrinsic ureteral obstruction: a survey of urologists and medical oncologists regarding treatment patterns and preferences. *Urology* 2008; **72**: 51-56 [PMID: 18372019 DOI: 10.1016/j.urology.2008.01.046]

83 **Little B**, Ho KJ, Gawley S, Young M. Use of nephrostomy tubes in ureteric obstruction from incurable malignancy. *Int J Clin Pract* 2003; **57**: 180-181 [PMID: 12723719]

84 **Lapitan MC**, Buckley BS. Impact of palliative urinary diversion by percutaneous nephrostomy drainage and ureteral stenting among patients with advanced cervical cancer and obstructive uropathy: a prospective cohort. *J Obstet Gynaecol Res* 2011; **37**: 1061-1070 [PMID: 21481096 DOI: 10.1111/j.1447-0756.2010.01486.x]

85 **Hyppolite JC**, Daniels ID, Friedman EA. Obstructive uropathy in gynecologic malignancy. Detrimental effect of intraureteral stent placement and value of percutaneous nephrostomy. *ASAIO J* 1995; **41**: M318-M323 [PMID: 8573816]

86 **Pietropaolo A**, Seoane LM, Abadia AA, Geraghty R, Kallidonis P, Tailly T, Modi S, Tzelves L, Sarica K, Gozen A, Emiliani E, Sener E, Rai BP, Hameed ZBM, Liatsikos E, Rivas JG, Skolarikos A, Somani BK. Emergency upper urinary tract decompression: double-J stent or nephrostomy? A European YAU/ESUT/EULIS/BSIR survey among urologists and radiologists. *World J Urol* 2022; **40**: 1629-1636 [PMID: 35286423 DOI: 10.1007/s00345-022-03979-4]

87 **Warnock DG,** Powell TC, Siew ED, Donnelly JP, Wang HE, Mehta RL. Serum Creatinine Trajectories for Community- vs Hospital-Acquired Acute Kidney Injury. Nephron 2016; 134: 177-182 [DOI: 10.1159/000447757]

88 **Siew ED**, Davenport A. The growth of acute kidney injury: a rising tide or just closer attention to detail? *Kidney Int* 2015; **87**: 46-61 [PMID: 25229340 DOI: 10.1038/ki.2014.293]

89 **Gadelkareem RA,** Abdelraouf AM, Ahmed AI, El-Taher AM, Behnsawy HM. Predictors of time-to-nadir serum creatinine after drainage of bilaterally obstructed kidneys due to bladder cancer. *Curr Urol* 2022 [DOI:10.1097/cu9.0000000000000166]

90 **Donat SM**, Russo P. Ureteral decompression in advanced nonurologic malignancies. *Ann Surg Oncol* 1996; **3**: 393-399 [PMID: 8790853 DOI: 10.1007/BF02305670]

91 **Gebreselassie KH**, Gebrehiwot FG, Hailu HE, Beyene AD, Hassen SM, Mummed FO, Issack FH. Emergency Decompression of Obstructive Uropathy Using Percutaneous Nephrostomy: Disease Pattern and Treatment Outcome at Two Urology Centers in Ethiopia. *Open Access Emerg Med* 2022; **14**: 15-24 [PMID: 35046735 DOI: 10.2147/OAEM.S344744]

92 **Ohtaka M**, Kawahara T, Takamoto D, Mochizuki T, Hattori Y, Teranishi JI, Makiyama K, Miyoshi Y, Yumura Y, Yao M, Uemura H. Gastrointestinal cancer and bilateral hydronephrosis resulted in a high risk of ureteral stent failure. *BMC Urol* 2018; **18**: 35 [PMID: 29739370 DOI: 10.1186/s12894-018-0346-3]

93 **Tatenuma T**, Tsutsumi S, Yasui M, Noguchi G, Umemoto S, Kishida T. Outcome of Palliative Urinary Diversion and Observation for Malignant Extrinsic Ureteral Obstruction. *J Palliat Med* 2020; **23**: 254-258 [PMID: 31834827 DOI: 10.1089/jpm.2019.0038]

94 **Azuma T**, Nagase Y, Oshi M. Prognostic marker for patients with malignant ureter obstruction. *Clin Genitourin Cancer* 2013; **11**: 353-356 [PMID: 23787166 DOI: 10.1016/j.clgc.2013.04.030]

95 **Mason JB**, Creswell M, Egan J, Dall C, Sholklapper T, Galloway LA, Orzel J, Lee H, Desale S, Stamatakis L. Prognostic factors for overall survival in malignant ureteral obstruction. *Can J Urol* 2022; **29**: 11162-11169 [PMID: 35691038]

96 **Alawneh A**, Tuqan W, Innabi A, Al-Nimer Y, Azzouqah O, Rimawi D, Taqash A, Elkhatib M, Klepstad P. Clinical Factors Associated With a Short Survival Time After Percutaneous Nephrostomy for Ureteric Obstruction in Cancer Patients: An Updated Model. *J Pain Symptom Manage* 2016; **51**: 255-261 [PMID: 26497918 DOI: 10.1016/j.jpainsymman.2015.09.009]

97 **Matsuura H**, Arase S, Hori Y. Ureteral stents for malignant extrinsic ureteral obstruction: outcomes and factors predicting stent failure. *Int J Clin Oncol* 2019; **24**: 306-312 [PMID: 30298199 DOI: 10.1007/s10147-018-1348-6]

98 **Matsuura H**, Arase S, Hori Y. Clinical outcomes and prognostic factors associated with internal ureteral stent placement for malignant extrinsic ureteral obstruction. *Support Care Cancer* 2020; **28**: 5743-5750 [PMID: 32206969 DOI: 10.1007/s00520-020-05413-0]

99 **Pavlovic K**, Lange D, Chew BH. Stents for malignant ureteral obstruction. *Asian J Urol* 2016; **3**: 142-149 [PMID: 29264182 DOI: 10.1016/j.ajur.2016.04.002]

100 **Wu KJ**, Chen YZ, Chen M, Chen YH. Clinical factors predicting ureteral stent failure in patients with external ureteral compression. *Open Med (Wars)* 2021; **16**: 1299-1305 [PMID: 34541328 DOI: 10.1515/med-2021-0345]

101 **Bigum LH**, Spielmann ME, Juhl G, Rasmussen A. A qualitative study exploring male cancer patients' experiences with percutaneous nephrostomy. *Scand J Urol* 2015; **49**: 162-168 [PMID: 25434764 DOI: 10.3109/21681805.2014.938694]

102 **Prentice J**, Amer T, Tasleem A, Aboumarzouk O. Malignant ureteric obstruction decompression: how much gain for how much pain? A narrative review. *J R Soc Med* 2018; **111**: 125-135 [PMID: 29648512 DOI: 10.1177/0141076818766725]

**Footnotes**

**Conflict-of-interest statement:** The authors report having no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author’s Membership in Professional Societies:** Egyptian Urological Association

**Peer-review started:** September 19, 2022

**First decision:** October 12, 2022

**Article in press:**

**Specialty type:** Urology and nephrology

**Country/Territory of origin:** Egypt

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Favi E, Italy; Sureshkumar KK, United States **S-Editor:** Xing YX **L-Editor:** Filipodia **P-Editor:** Xing YX

**Table 1 Summary of studies of reporting drainage of bilaterally obstructed kidneys due to malignant ureteral obstruction during the period of 2000-2022**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Study | | Patients | | | Underlying pathology | | Drainage | | Outcomes | | |
| Ref., yr | **Type** | **Number** | **Age mean ± SD or median (range) in yr** | **Male/female** | **Nature of obstruction** | **Primary site (IC and EC); Type of malignancy** | **Tool/Approach** | **Unilateral/bilateral** | **Technical success rate** | **Overall patient survival time and survival rate** | **Preference/conclusion/recommendation** |
| Pappas *et al*[9], 2000 | Retrospective, comparative | 159 | 65.1 (18.0-94.0) | 102/57 | BUO (30), MUO (125), and unknown (4) | IC: bladder and prostatic (NA) | PCN *vs* JJ | 149/10 | 99% for PCN | 227 d | PCN is safe and effective |
| 81% for JJ | Mean SCr improved from 6.9 mg/dL to 2.2 mg/dL |
| EC: GIT and Gyn (NA) |
| Ekici *et al*[10], 2001 | Retrospective series | 23 | 55 (25–76) | 21/2 | MUO | IC: bladder only (23) | PCN | NA | 100% | 4.9 mo | PCN is safe to avoid uremia |
| Chitale *et al*[11], 2002 | Retrospective cohort | 65 | NA (53–84) | 52/13 | MUO | IC: bladder (30) and prostatic (28) | Retrograde (24) *vs* PCN/antegrade JJ (41) | NA | PCN: 100% | 1-yr survival rate was 54.8% | Two-stage antegrade JJ was preferred |
| JJ: 21%/98.3% |
| EC: cervical (4) and rectal (3) |
| Chung *et al*[12], 2004 | Retrospective cohort | 101 | 61.4 (33.0–90.0) | 44/57 | BUO (11) and MUO (90) | IC: renal (2), bladder (2) and prostatic (5) | JJ | 65/36 | 95% | NA | 40.6% JJ failure at 11 mo; in 50% was due to compression |
| EC: GIT (35), uterine (8), ovarian (5), pancreatic (2), lymphoma (12), breast (13) and other (6) |
| Ku *et al*[13], 2004 | Retrospective, comparative | 148 | 57.3 (20.0-84.0) | 68/80 | MUO | EC: NA | PCN (80)/JJ (68) | 108/40 | 98.7%/89.0% | NA | PCN is superior to achieve decompression |
| Danilovic *et al*[14], 2005 | Retrospective cohort | 43 | 50.8 (25.0-84.0) | 16/27 | MUO (25) and BUO | IC (7): ureteral (1), bladder (1) and prostatic (4) | JJ initially; if failed, PCN was placed | 39/4 | 9% (for IC)/53% (for EC) | NA | PCN might be better for patients with EC |
| EC (36): uterine (9), ovarian (2), colorectal (4), and other (3) |
| Ganatra *et al*[15], 2005 | Retrospective cohort | 157 | 54.7 (23.0-83.0) | NA | MUO | IC: bladder (2) | PCN (24)/JJ (133) | NA | 64.3% | 11-mo survival rate was 75.8% | Bladder invasion predicts failure of JJ placement |
| EC: ovarian (26), cervical (16), GIT (32), breast (8), testicular (6) and others (68) |
| Romero *et al*[16], 2005 | Retrospective cohort | 43 | 52 (22-88) | 14/29 | MUO | IC: bladder (10) and prostate (5) | PCN | NA | 100% | Mean 12-mo survival rate was 24.2% | PCN drainage is better for those <52 yr |
| EC: cervical (23), ovary (7), and vulva (2) |
| Rosenberg *et al*[17], 2005 | Retrospective, comparative | 28 | 51 (21-78) | 1/27 | MUO | IC: none | Retrograde JJ; PCN alternative | NA | 92% | 15.3 mo; 14 patients died from malignancy during study | JJ is recommended to avoid dialysis |
| EC: uterine (14), ovarian (4), GIT (9) and breast (1) |
| Mean SCr improved from 2.9 mg/dL to 1.2 mg/dL |
| Uthappa *et al*[18], 2005 | Retrospective cohort | 30 | 61.4 (29.0-90.0) | 19/11 | MUO | IC: renal (2), ureteral (1), bladder (5), and prostatic (5) | Retrograde JJ; antegrade JJ was alternative | 10/20 | 50% | NA | Retrograde JJ initial method |
| EC: ovarian (4), uterine (5), rectal (3), testicular (1), GIT (2), and breast (2) |
| Wilson *et al*[19], 2005 | Retrospective cohort | 32 | 68.1 (24.0-84.0) | 16/16 | MUO | IC: bladder (8) and prostatic (9) | PCN; JJ was a second step in 32 patients | 12/20 | 100% | 87 d | PCN is best initially and recommended when there is a definitive plan for treatment |
| EC: Gynecological (7), colorectal (7), and breast (1) |
| Radecka *et al*[20], 2006 | Retrospective cohort | 151 | 73.1 (51.0-97.0) | 112/39 | MUO | IC: renal (4), ureteral (7), bladder (43), and prostatic (55) | PCN | 45/106 | NA | 255 d; 80% died with PCN | PCN for safety and cost |
| EC: Gyn (11), colorectal (16), and others (15) |
| Kano *et al*[21], 2007 | Retrospective, comparative | 75 | 62.7 (36.0-90.0) | 30/45 | MUO | IC: bladder (4) and prostate (11) | PCN (24)/JJ (51) | NA | 100/72.5; only 78.4% of those started with JJ completed | 5.9 mo and 5.6 mo for PCN and JJ, respectively | Initial trial of JJ without side holes, PCN is alternative |
| EC: uterine (25), GIT (28), ovarian (4), retroperitoneal (2), and lymphoma (1) |
| 1Rosevear *et al*[22], 2007 | Retrospective cohort | 54 | 61 (32-82) | 27/27 | BUO and MUO | IC: prostatic (5) | Retrograde JJ | 21/33 | 81 | Mean 16 mo | Retrograde JJ considered first line for MUO due to EC |
| EC: GIT (18), lymphoma (15), ovarian (50), uterine (6), and others (4) |
| Wong *et al*[23], 2007 | Retrospective cohort | 102 | 62 (31-86) | 45/57 | MUO | IC (30): bladder and prostatic | PCN/Retrograde JJ | 77/25 | 94%; 99% and 84% for PCN and JJ, respectively | 6.8 mo; 12 mo rate was 29% | Prognostic factors; PCN, metastases, and MUO diagnosis in established malignancy |
| EC: Gyn (32), GIT (21), lymphoma (5), and other (14) |
| Ishioka *et al*[24], 2008 | Retrospective cohort | 140 | 57 (31-85) | 60/80 | MUO | IC: urothelial (13) | PCN | 138/2 | 100% | 96 d; 12-mo rate was 12% | Risk stratification of patients relative to 1-3 risk factors |
| EC: gastric (29), colorectal (34), ovarian (6), cervical (30) and other (23) |
| Mean SCr improved from 4.33 mg/dL to 1.39 mg/dL |
| McCullough *et al*[25], 2008 | Retrospective comparative | 57 | 69.5 (40.0-91.0) | 31/26 | MUO | IC: bladder (12) and prostatic (20) | Retrograde JJ; PCN alternative | NA | 54% | SCr improved by 50% immediately after drainage | SCr level at presentation can predict success of retrograde JJ |
| EC: Gyn (8), colorectal (7), lymphoma (2), and others (8) |
| Lienert *et al*[26], 2009 | Retrospective cohort | 49 | 71 (36-91) | 27/22 | MUO | IC: bladder (18) and prostatic (15) | PCN | 38/11 | 100% | 174 d; 53% (prostatic) and 82% (non-prostatic) patients died during study | Risk stratification of patients; relative risk factors to validate the prognostic model of Ishioka *et al*[24] |
| EC: colorectal (6), Gyn (5), sarcoma (2), pancreatic (2), and breast (1) |
| Mishra *et al*[27], 2009 | Retrospective, comparative | 15 | 44.5 (30.0-65.0) | 0/15 | MUO | EC: cervical (15) | PCN; JJ alternative | 1/14 | 100% | NA | Bilateral temporary PCN helps receive definitive or specific therapy and avoid dialysis |
| Mean SCr improved from 7.5 mg/dL to 0.9 mg/dL within 1-3 wk |
| Nariculam *et al*[28], 2009 | Retrospective, comparative | 25 | 71 (51-85) | 25/0 | MUO | IC: prostatic only | PCN | 7/18 | 100% | 7.5-mo | Unilateral and bilateral PCN drainage were similar |
| Mean SCr improved from 612 µmoL to 187 µmoL within 14 d |
| Jalbani *et al*[29], 2010 | Prospective cohort | 40 | NA (21-70) | 20/20 | MUO | IC: bladder (10) and prostatic (5) | PCN | 20/20 | 100% | 350 d for IC and 25 d for EC | PCN excellent initial intervention |
| EC: cervical (15), ovarian (2), rectal (3), gall bladder (1), breast (1), and lymphoma (3) | Mean SCr normalized in 62.5% |
| Kamiyama *et al*[30], 2011 | Retrospective cohort | 53 | 61 (32-92) | 22/31 | MUO | IC: prostatic (3) | JJ as initial tool | 20/33 | 95.3% | Drainage success 66% | Proposed algorithm of drainage based on primary site, performance status, and degree of hydronephrosis |
| EC: GIT (31), Gyn (13), breast (3), and lymphoma (3) |
| Migita *et al*[31], 2011 | Retrospective series | 25 | 61 (29-76) | 13/12 | MUO | EC: gastric (25) | Retrograde JJ (15); PCN alternative (5) | 4/21 | 80%/100% | 5.8 mo; 1-yr survival rate was 32% | Initial trial should be with JJ |
| Prognosis is usually poor; urinary diversion should be tailored per patient |
| Song *et al*[32], 2012 | Retrospective, comparative | 75 | 57.1 (20.0-85.0) | 0/75 | MUO | EC: uterine (26), cervical (26), ovarian (20), and other (3) | Retrograde JJ; PCN alternative | 66/9 | 81.3%; for PCN 100% | 9.1 mo | Retrograde JJ first-line option; with serum cystatin C > 2.5 and obstruction length > 3 cm, PCN is alternative |
| Misra *et al*[33], 2013 | Retrospective, case series | 22 | 75.1 (54-87) | 20/2 | MUO | IC: bladder (6) and prostate (12) | PCN; Antegrade JJ second step in 10 patients | 11/11 | 100%/77% | 78 d | PCN is effective but with significant morbidity and not prolonging life; decision of drainage made after full discussion |
| EC: Gyn (2) and rectal (2) |
| Cordeiro *et al*[34], 2016 | Prospective cohort | 208 | 61 (19-89) | 101/107 | MUO | IC: bladder (47) and prostatic (25) | Initial retrograde JJ (58); PCN as alternative (150) | 107/101 | 27.9%/100% | 144 d; 1-yr survival rate was 44.9% and 7.1% for favorable and unfavorable groups, respectively | Risk stratification model with three groups to determine usefulness of urinary diversion; favorable, intermediate, and unfavorable |
| EC: cervical/uterine (51), ovarian (10), colorectal (45), and other (30) |
| Efesoy *et al*[35], 2018 | Retrospective series | 362 | 43.2 | 203/159 | BUO and MUO (151) | IC: bladder (31) and prostatic (43) | Ultrasound-guided PCN; Seldinger or direct puncture techniques | 293/61 | 96.1% | NA | Ultrasound-guided PCN is recommended procedure |
| EC: cervical (57), uterine (6), ovarian (5), and rectal (9) |
| Tan *et al*[36], 2019 | Retrospective, comparative | 89 | 50.3 (25.0-78.0) | 0/89 | MUO | EC: cervical (89) | Retrograde JJ; PCN alternative | 67/22 | 77.5%/100% | 100% | No differences between JJ and PCN outcomes |
| Drainage using JJ is preferred generally, but PCN is better in patients with severe hydronephrosis and long-segment ureteral obstruction (> 3 cm) |
| Tibana *et al*[37], 2019 | Retrospective, comparative | 41 | 65.6 ± 9.5 | 23/18 | MUO | IC: bladder (12) and prostatic (9) | PCN; Antegrade JJ | 10/16 | NA | NA | Antegrade JJ is alternative to PCN and retrograde JJ; clinical improvement in 97.5% |
| EC: uterine (11), ovarian (1), colorectal (7), and retroperitoneal (1) |
| 2Haas *et al*[8], 2020 | Retrospective database study | 238528 | 65.5 ± 14.6 | 47.6%/52.4% | MUO | IC: bladder (9.8%), prostatic (17.9%), and other (4.2%) | Retrograde JJ (18%)/PCN (11.4%) | NA | NA | Death in hospital rate was 7.3% | There was a substantial variation in approaching MUO with temporal decline in use of JJ but steady use of PCN with higher use in metastatic cases |
| EC: GIT (24.3%), Gyn (20.8%), lymphoma (10.3%), and other (15%) |
| Patients with urologic malignancies were older |
| De Lorenzis *et al*[38], 2020 | Retrospective, comparative | 51 | 70 (58-76) | 20/31 | MUO | EC only: colonic (28), rectal (14), gastric (5), pancreatic (3), and appendicular (1) | Retrograde JJ; PCN | 30/21 | 80.4%/ 100% | 10.5 mo; survival rate was 15.7% | GIT cancers causing MUO were associated with poor prognosis |
| Folkard *et al*[39], 2020 | Retrospective multicenter series | 105 | 68.8 (30.0-93.0) | 55/50 | MUO | IC (54): bladder and prostatic | PCN; Antegrade JJ second step in 62% | 46%/54% | 100% | 139 d; 4-yr survival rate was 24.8%. Only 30.5% underwent further oncological treatment | Mean SCr improved from 348 µmmol/L to 170 µmmol/L |
| EC (51): Gyn, colorectal, and other |
| Izumi *et al*[40], 2021 | Prospective multicenter comparative | 300 | 68 (25-96) | 126/174 | MUO | IC: bladder (19), ureter (13), prostatic (12), and other (6) | PCN (44)/JJ (217) | 161/139 | NA | Median survival times (1-yr survival rate) of the good, intermediate, and poor risk groups were 406 (54.4%), 221 (32.7%), and 77 (8%) d, respectively | Risk stratification proposed based on primary site of malignancy, laterality of MUO, SCr level, and treatment for primary site (PLaCT); Good, intermediate and poor risk groups |
| EC: Gyn (66), GIT (121), lymphoma (26), and other (37) |
| Gadelkareem *et al*[5], 2022 | Prospective, non-randomized | 107 | 56.6 | 68/39 | BUO (53) and MUO (54) | IC: bladder (30) and prostatic (5) | PCN (79) and JJ (28) | 57/50 | 98.3%/96.6% | NA | PCN is more suitable to MUO |
| EC: colorectal (11), cervical (6), and lymphoma (2) | Mean SCr improved from 6.1 mg/dL to 1.2 mg/dL |
| Kbirou *et al*[41], 2022 | Retrospective cohort | 102 | 60 (36-84) | 0/102 | MUO | EC: cervical (95), uterine (5), and ovarian (2) | PCN (94)/JJ (8) | NA | 100% | NA; 88% of patients had normalized kidney function | PCN is the main tool of drainage |
| Early diagnosis may enable prevention of MUO |
| Pickersgill *et al*[42], 2022 | Retrospective cohort | 78 | NA | NA | MUO | EC | JJ; PCN alternative | NA | Median (range) of JJ exchange was 2 (0–17) | 19.9 mo | JJ failure was high, warranting early use of PCN in management of MUO |

1Underlying malignancies were classified according to the primary site or origin as malignancy from the urological system, which was named intrinsic cancer and malignancy from other or distant systems or organs which was named extrinsic cancer.

2The values of the subtypes of malignancy were provided as a percentage due to the large number of cases. BUO: Benign ureteral obstruction, EC: Extrinsic cancer, IC: Intrinsic cancer; GIT: Gastrointestinal tract, Gyn: Gynecological, JJ: Double-J stent, MUO: Malignant ureteral obstruction, PCN: Percutaneous nephrostomy, NA: Not available; SCr; Serum creatinine, SD: Standard deviation.

**Table 2 Comparison between the drainage of kidneys with malignant ureteral obstruction by percutaneous nephrostomy *vs* double-J stent approach**

|  |  |  |
| --- | --- | --- |
| 1Variables | Drainage by PCN | Drainage by JJ |
| Design of catheter | | |
| Manufacturing characteristics | One-end coil kidney tube, with a need for fixation to the skin or change by a Foley catheter after tract establishment | Two-coil self-retaining internal ureteral catheter |
| Material: different, including polymeric and metallic types |
| Material: polymeric materials |
| Route of drainage | Drain the kidney to outside the body | Drain the kidney to urinary bladder |
| Length | Suitable to the skin-to-pelvicalyceal distance | Suitable to the ureteral length |
| Mechanism of drainage | Catheter lumen only | Ureteral lumen plus catheter lumen |
| Procedure/Technique | | |
| Armamentarium required | Needs radiological or ultrasonographic localization of the target calyx | Needs endoscopic armamentarium; C-arm and cystoscope |
| Approach | External and artificial | Internal and natural/artificial (antegrade) |
| Anesthesia | Mostly local | Local, epidural, or spinal |
| Feasibility | Independent on ureteral patency | Dependent on ureteral patency |
| Equally feasible to external and internal MUO | More feasible to external (compressive) MUO |
| Procedural time | Longer | Shorter |
| Preference and indications | The advanced stages | The early stages |
| Success rate | High; up to 96%–100% | Relatively low, up to 85% |
| Drainage and complications | | |
| Complications | They are dependent on the non-natural route (more invasive), with a greater incidence of injury of adjacent organs, hemorrhage, discomfort, obstruction, and accidental tube displacement | They are dependent on the internal route, with higher possibilities of LUTS, UTI, hematuria, and potential obstruction by underlying malignancy |
| Mechanism of failure of drainage | Mainly due to lumen obstruction by thick urinary contents and tube slippage | Mainly due to compression of the ureteral and stent lumens by the underlying malignancy |
| Effects on the outcomes | | |
| Kidney drainage and decompression | No statistical differences, but it is better with PCN, especially with infections | Lower efficacy |
| Normalization of functions | No difference | |
| Patient survival | No difference | |
| Hospital stay | Longer | Shorter |
| Periodical change of catheter | No difference | |
| Overall rate of complications | No difference | |
| Potential effect on quality of life | Higher due to external nature of urine drainage | Lower due to internal nature of drainage |

1The variables, classifications, and information provided in this table are drawn from the current literature, specifically within the last two decades[9,12–14,17,21,33,43,44].

MUO: Malignant ureteral obstruction; JJ: Double-J stent; LUTS: Lower urinary tract symptoms; PCN: Percutaneous nephrostomy; UTI: Urinary tract infection.